Sarah Cannon Research Institute

OncoGenex’s phase II Rainier study shows poor results

Thursday, September 24, 2015

OncoGenex Pharmaceuticals has reported initial results from the phase II Rainier study evaluating apatorsen in combination with Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to Abraxane and gemcitabine alone in patients with untreated metastatic pancreatic cancer. The addition of apatorsen to Abraxane and gemcitabine did not demonstrate a survival benefit compared to Abraxane and gemcitabine alone. The study was sponsored and conducted by Sarah Cannon Research Institute (SCRI).

[Read More]

Morphotek announces initiation of phase I study for MORAb-066

Wednesday, July 3, 2013

Biopharmaceutical Morphotek, a subsidiary of Eisai, has announced that the Sarah Cannon Research Institute in Nashville, Tenn., has opened enrollment in a phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies. The open-label, phase I study will assess the safety, tolerability and pharmacokinetics of MORAb-066 administered with weekly intravenous infusions.

[Read More]

Marshall Edwards initiates phase I ME-143 trial

Friday, September 9, 2011

Marshall Edwards, an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, has initiated a phase I clinical trial of its lead drug candidate ME-143 in patients with refractory solid tumors. The trial is being conducted in collaboration with the Sarah Cannon Research Institute in Nashville, Tennessee, following the approval of an Investigational New Drug (IND) application by the FDA last month.

[Read More]

Sarah Cannon Names New CFO

Friday, March 19, 2010

Strategic research organization Sarah Cannon Research Institute (SCRI) appointed Dean Ferrigno as chief financial officer (CFO), replacing Phil Cestaro, who is now president, SCRI Services. SCRI Services specializes in clinical trial administration with a focus on oncology drug development programs. Cestaro, who joined the company in 2006, will continue to be SCRI’s chief information officer in addition to the new position.

[Read More]